Secukinumab: The Anti-IL-17A Biologic for the Treatment of Psoriasis.
作者信息
Fargnoli Maria Concetta
机构信息
Department of Dermatology, University of L'Aquila, L'Aquila, Italy.
出版信息
Case Rep Dermatol. 2019 Sep 20;11(Suppl 1):1-3. doi: 10.1159/000501991. eCollection 2019 Sep-Dec.
Abstract
摘要
相似文献
1
Secukinumab: The Anti-IL-17A Biologic for the Treatment of Psoriasis.司库奇尤单抗：用于治疗银屑病的抗白细胞介素-17A生物制剂。
Case Rep Dermatol. 2019 Sep 20;11(Suppl 1):1-3. doi: 10.1159/000501991. eCollection 2019 Sep-Dec.
2
IκBζ is a key player in the antipsoriatic effects of secukinumab.IκBζ 是司库奇尤单抗抗银屑病作用的关键因子。
J Allergy Clin Immunol. 2020 Jan;145(1):379-390. doi: 10.1016/j.jaci.2019.09.029. Epub 2019 Oct 14.
3
Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis.司库奇尤单抗：一种用于治疗银屑病的抗白细胞介素-17A生物制剂的综述。
Ther Adv Chronic Dis. 2018 Jan;9(1):5-21. doi: 10.1177/2040622317738910. Epub 2017 Nov 16.
4
Secukinumab - First in Class Interleukin-17A Inhibitor for the Treatment of Psoriasis.司库奇尤单抗——首个用于治疗银屑病的白细胞介素-17A抑制剂。
Indian J Dermatol. 2017 Mar-Apr;62(2):195-199. doi: 10.4103/ijd.IJD_233_16.
5
No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.无需改变药物类别：在银屑病中，司库奇尤单抗治疗后使用依奇珠单抗。
J Dermatolog Treat. 2019 May;30(3):216-220. doi: 10.1080/09546634.2018.1506081. Epub 2018 Sep 11.
6
Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis.司库奇尤单抗，一种全人源抗白细胞介素-17A 单克隆抗体，在中重度斑块型银屑病患者中显示出最小的免疫原性。
Br J Dermatol. 2017 Mar;176(3):752-758. doi: 10.1111/bjd.14965. Epub 2016 Nov 22.
7
Secukinumab in the treatment of psoriasis: patient selection and perspectives.司库奇尤单抗治疗银屑病：患者选择与展望
Psoriasis (Auckl). 2018 Oct 17;8:75-82. doi: 10.2147/PTT.S146004. eCollection 2018.
8
β-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis.β-防御素 2 是银屑病患者中由 IL-17A 驱动的皮肤病理的反应性生物标志物。
J Allergy Clin Immunol. 2017 Mar;139(3):923-932.e8. doi: 10.1016/j.jaci.2016.06.038. Epub 2016 Aug 5.
9
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.古塞库单抗与司库奇尤单抗治疗中重度银屑病（ECLIPSE）：一项 3 期随机对照临床试验的结果。
Lancet. 2019 Sep 7;394(10201):831-839. doi: 10.1016/S0140-6736(19)31773-8. Epub 2019 Aug 8.
10
Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis.司库奇尤单抗治疗中重度斑块状银屑病的临床与经济学综述
Expert Rev Pharmacoecon Outcomes Res. 2016;16(2):153-66. doi: 10.1586/14737167.2016.1133301. Epub 2016 Feb 2.
引用本文的文献
1
The Effect of Unconventional Cytokine Combinations on NK-Cell Responses to Viral Infection.非常规细胞因子组合对 NK 细胞抗病毒感染反应的影响。
Front Immunol. 2021 Mar 19;12:645850. doi: 10.3389/fimmu.2021.645850. eCollection 2021.
2
Circulating CD14HLA-DR Myeloid-Derived Suppressor Cells as Potential Biomarkers for the Identification of Psoriasis TCM Blood-Heat Syndrome and Blood-Stasis Syndrome.循环CD14+HLA-DR髓源性抑制细胞作为识别银屑病中医血热证和血瘀证潜在生物标志物的研究
Evid Based Complement Alternat Med. 2020 Apr 14;2020:4582459. doi: 10.1155/2020/4582459. eCollection 2020.
本文引用的文献
1
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results).在中度至重度斑块状银屑病患者的皮肤清除方面，司库奇尤单抗优于优特克单抗（16周CLARITY研究结果）。
Dermatol Ther (Heidelb). 2018 Dec;8(4):571-579. doi: 10.1007/s13555-018-0265-y. Epub 2018 Oct 17.
2
Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation.司库奇尤单抗治疗中重度斑块状银屑病：一项多中心、回顾性、真实世界研究，观察至 52 周。
Expert Opin Biol Ther. 2018 Jul;18(7):727-735. doi: 10.1080/14712598.2018.1481503. Epub 2018 Jun 6.
3
Secukinumab in multi-failure psoriatic patients: the last hope?司库奇尤单抗用于多重治疗失败的银屑病患者：最后的希望？
J Dermatolog Treat. 2018 Sep;29(6):583-585. doi: 10.1080/09546634.2018.1427206. Epub 2018 Jan 23.
4
Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: A retrospective multicenter study.69 例中重度斑块型银屑病患者使用司库奇尤单抗的有效性和安全性：一项回顾性多中心研究。
Dermatol Ther. 2017 Nov;30(6). doi: 10.1111/dth.12550. Epub 2017 Sep 14.
5
Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real-world Canadian dermatology clinics: a multicenter retrospective study.司库奇尤单抗治疗加拿大两家实际临床皮肤科诊所中重度斑块状银屑病的疗效与安全性：一项多中心回顾性研究
J Eur Acad Dermatol Venereol. 2018 Jan;32(1):e32-e34. doi: 10.1111/jdv.14468. Epub 2017 Aug 2.
6
Secukinumab: A New Treatment Option for Psoriatic Arthritis.司库奇尤单抗：银屑病关节炎的一种新治疗选择。
Rheumatol Ther. 2016 Jun;3(1):5-29. doi: 10.1007/s40744-016-0031-5. Epub 2016 Apr 23.
7
Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial.司库奇尤单抗治疗掌跖银屑病的疗效显著：来自 GESTURE 的一项随机对照试验结果。
J Am Acad Dermatol. 2017 Jan;76(1):70-80. doi: 10.1016/j.jaad.2016.07.058. Epub 2016 Oct 1.
8
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.司库奇尤单抗在清除中重度斑块型银屑病患者皮肤方面优于乌司奴单抗：来自 CLEAR 研究的结果。
J Am Acad Dermatol. 2017 Jan;76(1):60-69.e9. doi: 10.1016/j.jaad.2016.08.008. Epub 2016 Sep 20.
9
Clinical efficacy and safety of anti-IL-17 agents for the treatment of patients with psoriasis.抗白细胞介素-17制剂治疗银屑病患者的临床疗效与安全性。
Immunotherapy. 2015;7(9):1023-37. doi: 10.2217/imt.15.50. Epub 2015 Jun 9.
10
Secukinumab: first global approval.司库奇尤单抗：全球首次获批。
Drugs. 2015 Feb;75(3):329-38. doi: 10.1007/s40265-015-0359-0.
Zotero 插件